Table 3.
Adjusted Absolute VE and Corresponding 95% CIs Against Symptomatic COVID-19, Stratified by Age Group and by Age Group and History of Prior SARS-CoV-2 Infection
| Age, y | Overall | No Prior Infection | Prior Infection, >3 mo Ago |
|---|---|---|---|
| VE (95% CI) | VE (95% CI) | VE (95% CI) | |
| 5–11 | 60.17 (32.42–99.48) | 49.77 (9.77–72.04)a | 79.43 (64.48–88.09)a |
| 12–17 | 38.98 (17.49–98.80) | 27.60 (−2.61 to 48.92) | 61.77 (48.59–71.57) |
| 18–49 | 41.99 (35.67–95.09) | 29.71 (22.04–36.61) | 57.72 (53.73–61.36) |
| 50–64 | 36.15 (15.96–95.22) | 23.94 (10.74–35.20) | 55.03 (49.58–59.88) |
| ≥65 | 22.48 (16.75–39.75) | 21.51 (10.47–31.20) | 56.09 (48.89–62.29) |
Absolute VE compares those who received 2–4 original wild-type doses plus a BNT162b2 BA.4/5 bivalent vaccine ≥14 days before testing for SARS-CoV-2 and the unvaccinated. All models used generalized estimating equations (clustered on US Census region of pharmacy) and adjusted for age (continuous), gender, race/ethnicity, prior SARS-CoV-2 infection, calendar week of SARS-CoV-2 test (categorical; 2-week intervals), recent contact with someone with confirmed or presumed to have COVID-19, US Census region of pharmacy, and store-specific percent positivity in the week prior to the SARS-CoV-2 testing date.
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VE, vaccine effectiveness.
aTwo individuals with gender Other removed from the absolute model due to zero cell errors when stratified by prior infection and inability to compute estimates.